Istituto Oncologico Veneto IRCCS
The Veneto region's OECI-accredited comprehensive cancer centre in Padua, strong in breast cancer trials, melanoma and tumour immunology.
Founded in 2005, the Istituto Oncologico Veneto is the IRCCS cancer institute of the Veneto region and coordinates the regional oncology network; it is accredited by the OECI as a comprehensive cancer centre. Pierfranco Conte and Valentina Guarneri's breast oncology group led the ShortHER trial of trastuzumab duration and many neoadjuvant studies, the melanoma unit is a leading Italian immunotherapy trial site, and Vincenzo Bronte's immunology programme is known for myeloid-derived suppressor cells. The institute runs gastrointestinal, thoracic and gynaecological oncology, radiotherapy and nuclear medicine across Padua and Castelfranco Veneto, with a phase 1 unit and the University of Padua's oncology school.
- Breast cancer trials
- Melanoma immunotherapy
- Tumour immunology (myeloid cells)
- Veneto oncology network
- Phase 1 unit
Pages like this
not linked directly; found by shared links- InstitutionMasaryk Memorial Cancer Institute
Shares Organisation of European Cancer Institutes, Melanoma, Immune checkpoint inhibitors, HR-positive / HER2-negative breast cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Alexander Fleming
Shares Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionNational Institute of Oncology, Hungary
Shares Organisation of European Cancer Institutes, Melanoma, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaTime immunotherapy to the moment targeted drugs make tumours visible
Shares CDK4/6 inhibitors, Melanoma, Immune checkpoint inhibitors, HR-positive / HER2-negative breast cancer.
- InstitutionInstitute of Oncology Ljubljana
Shares Organisation of European Cancer Institutes, Melanoma, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionInstitut Jules Bordet
Shares Organisation of European Cancer Institutes, Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer.